High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
The completed acquisition adds PALSONIFY and atumelnant to Vertex’s portfolio, with the two therapies carrying combined peak annual revenue potential of more than $5 billion according to the company. Key Investor TakeawaysVertex Pharmaceuticals (NASDAQ:VRTX) completed its approximately $10 billion equity-value acquisition of Crinetics Pharmaceuticals on September 1, 2026.
A California biotech just raised $350 million promising to out-perform opioids without the addiction risk, and its auditors were still warning about survival just months ago. Here is what the science and the filings actually show.
Analysts expect new details on the lead-up to the deal “are likely to reignite” investor scrutiny that Vertex overpaid in what’s poised to be its largest-ever transaction.
The biotech's diversification efforts continue.
H.C. Wainwright said Crinetics’ lead product Palsonify adds a meaningful commercial product and establishes endocrinology as Vertex’s fifth major business pillar.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.